CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ — Harbour BioMed (“HBM” or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, announced a strategic collaboration in artificial intelligence (AI).
Under the terms of the collaboration, Harbour BioMed and Evinova China will jointly apply AI …
Leave a Reply
You must be logged in to post a comment.